Micro Algae Corporation

Mar 30, 2022

Commercial expansion in Asia and the United States Ramp-up in high EPA/DHA plant-based Omega 3 solutions Significant increase of its sustainable production capacity QUIMPER, France & PARIS–(BUSINESS WIRE)–Polaris, a pioneer in Omega3 and leader in fatty acids with high concentrations of EPA (eicosapentaenoic acid) and DHA (docosahexaenoic acid), which play a key role in cardiovascular, brain health and help to reinforce the immune system, has announced that it is raising €5 million, led by Seventure Partners, via its Health for Life Capital™ fund. This funding will allow the company which operates in Japan, South Korea and recently the United States, to continue its international expansion, strengthen its position in nutraceutical industry and specialized nutrition (children, sports, pregnancy) and to expand its sustainable production unit in Brittany, France. Polaris is a recognized leader in the EPA/ DHA market – worth an estimated USD 945 billion US $ in 2026 * – driven by the global nutrition transition, which is expected to grow sharply over the next few decades. Thanks to a sustained innovation dynamic, Polaris has imposed its expertise at global level to produce and to transform very high-quality polyunsaturated fatty acids. Since 2017, Polaris has developed and sold an innovative, sustainable solution derived from vegan micro-algae protected by a strong intellectual property. These products are a genuine alternative to Omega 3 fish oils. Of exceptionally high quality, allergen-free with a great organoleptic profile, i.e. offering clean taste and smell, they are very rich in EPA/DHA Omega 3 and meet the ...